Tag: Perphenazine

While both are antipsychotic medications, a key clinical distinction is their classification: risperidone is a newer, atypical (second-generation) antipsychotic, whereas perphenazine is an older, typical (first-generation) antipsychotic. This difference in drug class leads to variations in their mechanisms of action, side effect profiles, and typical uses.

Initially approved in 1957, perphenazine is a first-generation (typical) antipsychotic with a well-defined pharmacological profile. To comprehend its therapeutic effects and side effect risks, it is essential to understand **what is the mechanism of action of perphenazine**, which is centered on antagonizing a variety of neurotransmitter receptors in the brain.

First introduced in 1957, Trilafon (perphenazine) is a first-generation antipsychotic primarily used for treating schizophrenia and severe nausea and vomiting. While the brand name is no longer manufactured in the U.S., the generic form is still prescribed for these and other off-label conditions.